L-arginine ; sodium salt | 15690-14-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-arginine ; sodium salt
• 英文别名: L-Arginin; Natriumsalz；sodium;(2S)-2-amino-5-(diaminomethylideneamino)pentanoate
• CAS: 15690-14-9
• 化学式: C₆H₁₃N₄O₂*Na
• 分子量: 196.185
• InChiKey: YFGAFXCSLUUJRG-WCCKRBBISA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -5.88
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二苯基二烃基硼酸 、 L-arginine ; sodium salt 以 乙醚 、 水 为溶剂， 反应 4.0h， 以89%的产率得到diphenylboranyl (2S)-2-amino-5-(diaminomethylideneamino)pentanoate
  参考文献：
  名称：

  In vitro apoptotic activity of 2,2-diphenyl-1,3,2-oxazaborolidin-5-ones in L5178Y cells

  摘要：

  Compounds containing B-N bonds have shown interesting biological activity. One class of such molecules is the 2,2-diphenyl-1,3,2oxazaborolidin-5-ones (3a-j), which contain a B-N bond, have an alpha-amino acid moiety in the heterocycle, and have an exocyclic moiety related to an amino acid. The purpose of this work was to determine the inhibitory effects of 3a-j on the proliferation of murine L5178Y lymphoma cells. A new five-membered heterocyclic nucleus with apoptotic activity was found. The target products showed potent cytotoxicity in the L5178Y cell line. Among them, 3a exhibited the highest antineoplastic activity in L5178Y cells with an IC50 value of 22.5 +/- 0.2 mu M. (c) 2006 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.lfs.2006.11.034

文献信息

• [EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2018218251A1

  公开（公告）日：2018-11-29

  Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

  化合物的15-PGDH活性调节方法、组织前列腺素水平调节、疾病治疗、疾病紊乱或希望调节15-PGDH活性和/或前列腺素水平的状况包括本文描述的15-PGDH抑制剂。
• PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF
  申请人：Chen Ing-Jun

  公开号：US20120108604A1

  公开（公告）日：2012-05-03

  A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R 1 , R a and RX are as defined in the specification. The amine complex salts disclosed in the present invention are characterized in a pro-drug active form and various pharmaceutical function.

  提供了一系列包括公式(I)和公式(III)结构的胺盐。在公式I或公式(III)中，R1、Ra和RX如说明书中所定义。本发明公开的胺络合盐具有前药活性形式和多种药理功能。
• Method for producing 1-substituted-1,2,3- triazole derivative
  申请人：——

  公开号：US20030069419A1

  公开（公告）日：2003-04-10

  A method for producing a compound of the formula: 1 (1) in a secondary or tertiary alcohol in the presence of a base, or (2) in the absence of a base is provided. According to this method, a 1-substituted-1,2,3-triazole compound having a tyrosine kinase inhibitory action can be produced efficiently in a high yield at an industrial large scale by a convenient method

  提供了一种制备以下公式化合物的方法： 1 (1) 在二级或三级醇中，在碱的存在下，或 (2) 在无碱的情况下进行。根据这种方法，可以通过一种方便的方法，在工业大规模下高效并以高收率地制备具有酪氨酸激酶抑制作用的1-取代-1,2,3-三唑化合物
• NOVEL PHENOL DERIVATIVE
  申请人：Kobashi Seiichi

  公开号：US20120184587A1

  公开（公告）日：2012-07-19

  Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1 ; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of the derivative or the salt. (In the formula, R 1 and R 2 may be the same or different and each represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a haloalkyl group, a haloalkoxy group, an alkylsulfanyl group, an alkylsulfinyl group, an alkylsulfonyl group, a lower alkyl-substituted carbamoyl group, a saturated nitrogen-containing heterocyclic N-carbonyl group, a halogen atom, a cyano group or a hydrogen atom; R 3 represents a lower alkyl group, a haloalkyl group, a halogen atom, a hydroxy group or a hydrogen atom; and X represents a sulfur atom, an —S(═O)— group or an —S(═O) 2 — group.)

  揭示了一种新型化合物和一种药物产品，每种都具有显著的利尿酸效果。具体揭示了：一种新型酚衍生物，其通式（1）如图1所示；其药学上可接受的盐；该衍生物或盐的水合物；以及该衍生物或盐的溶剂化合物。（在该式中，R1和R2可以相同也可以不同，每个代表较低的烷基基团、较低的烯基基团、较低的炔基基团、较低的烷氧基团、卤代烷基基团、卤代烷氧基团、烷基硫基团、烷基亚硫基团、烷基磺基团、较低烷基取代的氨基甲酰基团、饱和的含氮杂环N-羰基团、卤素原子、氰基或氢原子；R3代表较低的烷基基团、卤代烷基基团、卤素原子、羟基或氢原子；X代表硫原子、—S(═O)—基团或—S(═O)2—基团。）
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Miyata Toshio

  公开号：US20120022080A1

  公开（公告）日：2012-01-26

  The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

  本发明提供了一种具有纤溶酶原激活物抑制剂-1抑制活性的新化合物，以及包括该化合物作为活性成分的PAI-1抑制剂。本发明还提供了一种对PAI-1活性具有抑制作用且在预防和治疗与PAI-1活性相关的各种疾病方面有效的药物组合物。